NRX Pharmaceuticals

NRXP

Market cap $69.4M

Overview Fund Activity

2.92 USD

-0.06

2.01%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

2.97

+0.05

1.71%

1 day

-2.01%

5 days

-1.68%

1 month

5.8%

3 months

-12.57%

6 months

42.44%

Year to date

-2.34%

1 year

78.05%

5 years

-97.27%

10 years

-96.96%

About: NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

706% more call options, than puts

Call options by funds: $145K | Put options by funds: $18K

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

150% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 4

112% more capital invested

Capital invested by funds: $4.6M [Q1] → $9.76M (+$5.16M) [Q2]

14% more funds holding

Funds holding: 22 [Q1] → 25 (+3) [Q2]

1.99% more ownership

Funds ownership: 13.36% [Q1] → 15.35% (+1.99%) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$34

1,064% upside

Avg. target

$37

1,167% upside

High target

$40

1,270% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

D. Boral Capital Jason Kolbert	$34	Buy Maintained	8 Sep 2025
HC Wainwright & Co. Patrick R. Trucchio	$40	Buy Assumed	8 Sep 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about NRXP published over the past 30 days

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics

MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE) -- HOPE Therapeutics™, Inc. ("HOPE"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced the closing of the previously announced acquisition of Dura Medical (Dura). Dura, together with the pending Neurospa TMS and Cohen and Associates acquisitions, are planned to provide a comprehensive service offering to patients at more than 8 locations along the West Coast of Florida. Dura is revenue generating and EBITDA positive.

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics

NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th

WILMINGTON, Del., Sept. 03, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, today announced that Jonathan Javitt, M.D.

NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th

UPDATE -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller, Sponsored by Rockefeller Global Family Office

SOUTHAMPTON, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, presented two keynote talks to a gathering of leading family offices and family members sponsored by the Global Passion Project and the Rockefeller Global Family Office on August 28-30, 2025 in Southampton, NY. The Company's CEO, Prof. Jonathan Javitt, MD, MPH spoke alongside Matthew Rockefeller, Bradley Hilton and Cheryl Young of Rockefeller Capital, and representatives of leading family offices to detail plans for the Fall 2025 launch of HOPE Therapeutics clinics and a prospective unique one-week residential program targeting suicidal depression, PTSD, traumatic brain injury, and cognitive dysfunction. The HOPE residential program will be the nation's first to combine neuroplastic drugs, including ketamine, transcranial magnetic stimulation and hyperbaric oxygen therapy in a campus-like setting that adds nutritional therapy from one of the nation's leading chefs, neuroplastic-targeted outdoor activities, and supportive therapy. At the symposium, Matthew Rockefeller was announced as joining the advisory board of HOPE Therapeutics.

UPDATE -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller, Sponsored by Rockefeller Global Family Office

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital

SOUTHAMPTON, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, presented two keynote talks to a gathering of leading family offices and family members sponsored by the Global Passion Project and Rockefeller Capital on August 28-30, 2025 in Southampton, NY. The Company's CEO, Prof. Jonathan Javitt, MD, MPH spoke alongside Matthew Rockefeller, Bradley Hilton and Cheryl Young of Rockefeller Capital, and representatives of leading family offices to detail plans for the Fall 2025 launch of HOPE Therapeutics clinics and a prospective unique one-week residential program targeting suicidal depression, PTSD, traumatic brain injury, and cognitive dysfunction. The HOPE residential program will be the nation's first to combine neuroplastic drugs, including ketamine, transcranial magnetic stimulation and hyperbaric oxygen therapy in a campus-like setting that adds nutritional therapy from one of the nation's leading chefs, neuroplastic-targeted outdoor activities, and supportive therapy. At the symposium, Matthew Rockefeller was announced as joining the advisory board of HOPE Therapeutics.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)

WILMINGTON, Del., Aug. 27, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, today announced its expanded access policy for NRX-100 (preservative-free ketamine) based on grant of Fast Track designation for NRX-100 in the treatment of suicidal ideation in patients with depression, including bipolar depression.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)

NRx Pharmaceuticals, Inc. (NRXP) Q2 2025 Earnings Call Transcript

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q2 2025 Earnings Conference Call August 20, 2025 8:00 AM ET Company Participants Jonathan C. Javitt - Co-Founder, Chief Scientist Officer, Chairman & Interim CEO Matthew Patrick Duffy - Chief Business Officer & Co-CEO of Hope Therapeutics Michael S.

NRx Pharmaceuticals, Inc. (NRXP) Q2 2025 Earnings Call Transcript

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

NRx Drug Development Grant of expanded Fast Track Designation for NRX-100 from the FDA for all indications and types of depression and related disorders based on its potential to satisfy an unmet medical need. Represents an approximately 10-fold expansion of the addressable market to 13 million Americans, compared to the original Fast Track Designation issued in 2017 for bipolar depression alone.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025

Conference Call 8:00am ET, Wednesday August 20, 2025 WILMINGTON, Del. , Aug. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results after the market closes on Tuesday, August 19, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025

WILMINGTON, Del., Aug. 11, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results after the market closes on Thursday, August 14, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression

This designation expands the addressable population for NRX-100 to the 13 million Americans who consider suicide each year and represents a 10x expansion of the addressable population compared to the Designation granted in 2017 for bipolar depression alone The Designation includes an FDA determination that NRX-100 has the potential to address an unmet need, based on FDA's assessment of the data submitted Determination of "unmet need" is a requirement for a Commissioner's National Priority Voucher (CNPV) program. Suicide is a public health crisis.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression

See News Rankings

Charts implemented using Lightweight Charts™